Dr. Michael Yeomans

• 
  www.sec.gov/Archives/edgar/data/885590/0001047469-06-00 - [Cached Version]
  Published on: 4/3/2006    Last Visited: 4/4/2006  

  Michael Yeomans
  ...
  Dr. Yeomans is the Senior Vice President, Business Development.Before joining Biovail, Dr. Yeomans spent four years at Aventis Pharma, where he headed the company's Business Development group.Prior to joining Aventis in 2000, Dr. Yeomans spent more than 27 years with the Hoechst Group, where he held a series of progressively responsible senior positions in the United States and Germany and the United Kingdom.Dr. Yeomans earned his Ph.D. in Organic Chemistry and a B.Sc. Honors degree in Chemistry from the University of London.

• 
  www.ebdgroup.com/bioeurope/panel6.htm - [Cached Version]
  Published on: 11/6/2006    Last Visited: 3/14/2007  

  Dr. Michael A. Yeomans, Senior Vice President, Business Development Services, Biovail

• 
  www.ebdgroup.com/partneringnews/?q=node/23 - [Cached Version]
  Published on: 11/14/2007    Last Visited: 6/15/2008  

  Michaels Yeomans, Senior Vice President for Global Business Development and Licensing at Bayer Schering Pharma said, "We have a big group here and this is the first opportunity for our team to come together as a group since the merger."

• 
  www.windhover.com/dotcom/conferences/psa2007/psa_schedu - [Cached Version]
  Published on: 9/25/2007    Last Visited: 6/15/2008  

  Dr. Michael Yeomans, Senior Vice President Global Business Development & Licensing, Bayer Schering Pharma AG
  
  Michael Yeomans is the new business development face at Bayer Schering, set to become a formidable new force at the dealmaking table.

• 
  www.ebdgroup.com/partneringnews/?q=node/20 - [Cached Version]
  Published on: 11/14/2007    Last Visited: 6/15/2008  

  Joining Watson on the podium for the hour-long debate of strategic deal making issues were John G. Goddard with global responsibilities for AstraZeneca as the Senior Vice President for Strategic Planning and Business Development, Vincent Aurentz the Senior Executive Vice President for Portfolio Management and Business Development with Merck Serono International, Michael Yeomans the Senior Vice President of Global Business Development and Licensing at Bayer Schering Pharma, and Doug Giordano the Vice President of Worldwide Business Development for Pfizer.
  ...
  Yeomans at Bayer Schering Pharma said he was troubled by the growing complexity of deals where "its negotiations were no longer about upfront, milestone and royalty payments anymore but joint development and control of the development process.
  ...
  Complexity of deals is not restricted only to deals for building a portfolio by bringing an advanced asset to market but applies equally to discovery research where a pharma seeks to expand its pipeline through externalisation of development according to Yeomans.Control remains the hottest issue in negotiations today, he said, "How much control to keep, how much do you want the discovery partner to take remains the single biggest decision and there is no single answer to this.

• 
  www.ebdgroup.com/bioeurope/ws_panels.htm - [Cached Version]
  Published on: 10/6/2008    Last Visited: 9/15/2007  

  Michael Yeomans, SVP, Global Business Development & Licensing, Bayer Schering Pharma

• 
  www.ebdgroup.com/ebd/partneringnews/adayinthelife.htm - [Cached Version]
  Published on: 10/6/2008    Last Visited: 6/15/2008  

  Joining Watson on the podium for the hour-long debate of strategic deal making issues were John G. Goddard with global responsibilities for AstraZeneca as the Senior Vice President for Strategic Planning and Business Development, Vincent Aurentz the Senior Executive Vice President for Portfolio Management and Business Development with Merck Serono International, Michael Yeomans the Senior Vice President of Global Business Development and Licensing at Bayer Schering Pharma, and Doug Giordano the Vice President of Worldwide Business Development for Pfizer.
  ...
  Yeomans at Bayer Schering Pharma said he was troubled by the growing complexity of deals where "its negotiations were no longer about upfront, milestone and royalty payments anymore but joint development and control of the development process.
  ...
  Complexity of deals is not restricted only to deals for building a portfolio by bringing an advanced asset to market but applies equally to discovery research where a pharma seeks to expand its pipeline through externalisation of development according to Yeomans.
  
  Control remains the hottest issue in negotiations today, he said, "How much control to keep, how much do you want the discovery partner to take remains the single biggest decision and there is no single answer to this.

• 
  usa-canada.les.org/meetings/2007spring/schedule_glance. - [Cached Version]
  Published on: 1/1/2007    Last Visited: 3/3/2007  

  Michael Yeomans, Senior Vice-President, Global Business Development, Biovail Corporation

• 
  usa-canada.les.org/meetings/2007spring/plenary.asp - [Cached Version]
  Published on: 1/1/2007    Last Visited: 3/3/2007  

  Michael Yoemans, Senior Vice President, BioVail

• 
  2004 Annual Conference Program - [Cached Version]
  Published on: 8/7/2004    Last Visited: 6/12/2008  

  Michael Yeomans, Ph.D.Senior Vice President, Head of Global Business DevelopmentAventis, New Jersey

Page:  1 2